Blood-derived eye drops in liquid and powder form for the treatment of severe dry eye

Use of frozen and lyophilized blood components for the treatment of severe dry eye

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

REBEC

Registry ID

RBR-2gt5t4c

Enrollment

Registered

2026-04-27

Start date

2025-01-06

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndromes

Interventions

This study will be conducted to compare three types of eye drops prepared from the patient’s own blood and to determine whether there is any difference between using the drops in liquid form (conventi

Platelet-rich plasma eye drops: eye drops prepared from the portion of blood with a higher concentration of platelets (blood cells associated with healing)

Plasma rich in growth factors eye drops: eye drops prepared to concentrate substances in the blood called growth factors, which may help with recovery of the ocular surface. This will be a triple-blin

Eligibility

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with a diagnosis of severe mixed dry eye; Patients with a therapeutic indication for the use of topical blood components on the ocular surface; Patients who agree to participate in the study and sign the Informed Consent Form (ICF); Minimum age of 18 years; Both sexes

Exclusion criteria

Exclusion criteria: Patients with an active ocular infection at the time of data collection; Pregnant or lactating patients; Patients who have had changes in pre-existing topical eye medications after the start of the study; Patients unable to attend all evaluations required by the study protocol

Design outcomes

Primary

Measure	Time frame
It is expected that there will be no clinically relevant difference between the eye drops prepared by the conventional (liquid) method and the lyophilized eye drops in the treatment of dry eye, considering the symptom- and sign-based measures assessed at the end of 30 days of use in each phase of the study	—

Secondary

Measure	Time frame
It is expected to observe improvement in the dry eye parameters assessed with all storage/preparation methods of the eye drops (conventional and lyophilized), and no clinically relevant difference is expected among the types of blood-derived eye drops used (autologous serum, platelet-rich plasma, and plasma rich in growth factors)	—

Countries

Contacts

Public ContactMônica Alves

Universidade Estadual de Campinas

nucomhc@unicamp.br+55(19)35217396

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Jun 11, 2026